TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16501756

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach without nicotine replacement therapy (GB)
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 1 or 2 sessions (G1-G2) without NRT
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 3 or 4 sessions (G3-G4) without NRT
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with nicotine replacement therapy (GBA)
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 1 or 2 sessions (G1A-G2A) with NRT
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 3 or 4 sessions (G3A-G4A) with NRT
Number of subjects: 1199
Study: 12547849

Group type: EXPERIMENTAL
Intervention: Sildenafil (25-100 mg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 10695262

Group type: EXPERIMENTAL
Intervention: Exercise training (attending classes at least twice a week for 25 weeks, each lasting two hours)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (attending recreational classes twice a month)
Number of subjects: 65
Study: 9359554

Group type: EXPERIMENTAL
Intervention: Cardioselective beta blockers
Number of subjects: 12
Study: 8096545

Group type: EXPERIMENTAL
Intervention: 5 mg dose of ebastine syrup
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg dose of ebastine syrup
Number of subjects: 20
Study: 3805797

Group type: COMPARATOR
Intervention: Regimen I (WHO 1982 recommendations: Dapsone and six once a month rifampicin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Regimen II (Dapsone, rifampicin, and clofazimine 100 mg on alternate days)
Number of subjects: 80
Study: 31501611

Group type: EXPERIMENTAL
Intervention: Predicted VAT mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visceral fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (in females)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (in males)
Number of subjects: 0
Study: 29587805

Group type: EXPERIMENTAL
Intervention: Patient-centered recruitment strategies including trust, communication, attitude, and expectations.
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Active engagement and reminders at the offices.
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Telephone recruitment (site specific).
Number of subjects: 743
Study: 28641216

Group type: EXPERIMENTAL
Intervention: PEGASUS (8-session treatment)
Number of subjects: 179

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 179
Study: 24519767

Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy
Number of subjects: 390

Group type: COMPARATOR
Intervention: Unilateral mastectomy
Number of subjects: 390
Study: 24351088

Group type: EXPERIMENTAL
Intervention: Smartphone-supplemented iCBT with therapist support
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Smartphone-supplemented iCBT without therapist support
Number of subjects: 150

Group type: COMPARATOR
Intervention: Active waiting list control group with delayed treatment
Number of subjects: 150
Study: 20514964

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 1 microg/kg (group C1, n=39)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg/kg (group C2, n=41)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (group NS, n=40)
Number of subjects: 120
Study: 18628259

Group type: EXPERIMENTAL
Intervention: Positive Reappraisal Coping Intervention (PRCI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Positive Self‐Affirmative Intervention (PMI)
Number of subjects: 55
Study: 16623401

Group type: EXPERIMENTAL
Intervention: Minimal low-flow anesthesia (LFA) at 0.3 mL/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Semi-closed high flow anesthesia (HFA) at 2 L/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both LFA and HFA
Number of subjects: 40
Study: 14763696

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg bolus IV, followed by 1 mg/kg/hour continuous infusion for 10 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (20 mL saline IV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10762509

Group type: EXPERIMENTAL
Intervention: Passive body rotation (+/-30 degrees, 0.01 Hz) in darkness with head held stationary
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal subjects (10 subjects)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Left brain-damaged patients (2 patients)
Number of subjects: 7
Study: 7871655

Group type: EXPERIMENTAL
Intervention: Pikamilon administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 2893187

Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg 6‐hourly, 500 mg 6‐hourly, or 500 mg 12‐hourly)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acyclovir (with or without zidovudine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 18
Study: 30286443

Group type: COMPARATOR
Intervention: Alprazolam (2 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Dronabinol (10 mg and 30 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CBD (750 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CBD (1500 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CBD (4500 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Alprazolam and Dronabinol
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CBD (1500 mg and 4500 mg)
Number of subjects: 95
Study: 28052063

Group type: EXPERIMENTAL
Intervention: HMW cord blood adiponectin
Number of subjects: 181

Group type: COMPARATOR
Intervention: Child plasma HMW adiponectin
Number of subjects: 181
Study: 28130206

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg twice daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 23570278

Group type: EXPERIMENTAL
Intervention: Multifaceted tailored educational intervention for oncologists involving standardized patient instructors (SPIs)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Coaching intervention for patients and caregivers to facilitate prioritizing and discussing questions and concerns
Number of subjects: 400
Study: 21541241

Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy with gemcitabine (1250 mg/m² on days 1 and 4), cisplatin (75 mg/m² on day 2), and erlotinib (150 mg daily on days 5-15, followed by maintenance erlotinib)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy with gemcitabine, cisplatin, and erlotinib
Number of subjects: 24
Study: 19541016

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (0.067 g kg(‐1) h(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 16
Study: 17944739

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (botox) 4 x 25 U
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both treatments (botox and saline)
Number of subjects: 23
Study: 15178915

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Loratadine (10 mg/day)
Number of subjects: 52
Study: 11157322

Group type: EXPERIMENTAL
Intervention: Low fat diet (LF)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low fat and energy diet (LFE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low energy diet (LE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Typical fat diet (TF)
Number of subjects: 11
Study: 10101928

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic subjects
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic subjects with nephropathy and coronary vascular disease (CVD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Type II diabetics
Number of subjects: 86

Group type: COMPARATOR
Intervention: Overweight controls
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic patients with diabetic neuropathy, nephropathy or CHD
Number of subjects: 86
Study: 7833483

Group type: COMPARATOR
Intervention: Standard random single-donor platelet transfusions (mean leukocytes, 430 x 10(6) per transfusion)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted random single-donor platelet transfusions (mean leukocytes, 2 x 10(6) per transfusion)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard random single-donor platelet transfusions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted random single-donor platelet transfusions
Number of subjects: 75
Study: 2086423

Group type: EXPERIMENTAL
Intervention: Suction-cup oculopression (SCO; negative pressure -100 and -150 mmHg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia (RBA) with 5 ml of bupivacaine/lidocaine mixture with adrenaline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vörösmarthy oculopression (VMO; pressure 30 and 40 mmHg)
Number of subjects: 40
Study: 678373

Group type: EXPERIMENTAL
Intervention: Propanidid and lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing practice of non-depolarizing neuromuscular blocking drugs
Number of subjects: 0
Study: 31007057

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 47
Study: 29761313

Group type: EXPERIMENTAL
Intervention: Yisui Shengxue Granules (12 g/bag three times a day) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DNA methylation analysis from 5 patients in the experimental group
Number of subjects: 40
Study: 27456034

Group type: EXPERIMENTAL
Intervention: sarpogrelate in addition to aspirin
Number of subjects: 186

Group type: COMPARATOR
Intervention: non-sarpogrelate group
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: sarpogrelate
Number of subjects: 186

Group type: COMPARATOR
Intervention: non-sarpogrelate
Number of subjects: 186
Study: 25212518

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 343
Study: 23905874

Group type: EXPERIMENTAL
Intervention: Mentor now
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mentor later (waitlist control)
Number of subjects: 22
Study: 21610441

Group type: EXPERIMENTAL
Intervention: Lift-and-slide technique
Number of subjects: 6

Group type: COMPARATOR
Intervention: Log roll technique
Number of subjects: 6
Study: 19700005

Group type: EXPERIMENTAL
Intervention: Online CBT in addition to usual care (n=149)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual care from general practitioner while on an 8‐month waiting list for online CBT (n=148)
Number of subjects: 297
Study: 16701923

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (n=16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 30
Study: 15270891

Group type: EXPERIMENTAL
Intervention: Topical photodynamic therapy with methyl aminolaevulinate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11274904

Group type: EXPERIMENTAL
Intervention: Neuro-fuzzy control system (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional algorithm (control group B)
Number of subjects: 40
Study: 8996461

Group type: EXPERIMENTAL
Intervention: Conventional TENS applied to the ipsilateral forearm
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional TENS applied to the contralateral leg
Number of subjects: 16
Study: 7981402

Group type: EXPERIMENTAL
Intervention: Nonparametric approach for predictive distribution
Number of subjects: 0
Study: 3582898

Group type: EXPERIMENTAL
Intervention: Metenkephalin analogue (40 micrograms i.v.)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metenkephalin analogue (20 to 60 micrograms i.v.)
Number of subjects: 17
Study: 31365437

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy adapted for cognitive impairments (CBT‐ABI), 9 sessions
Number of subjects: 45
Study: 30032941

Group type: EXPERIMENTAL
Intervention: MICO therapist behaviors (simple reflections and paraphrasing reflections)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Complex reflections and open questions
Number of subjects: 132

Group type: COMPARATOR
Intervention: Closed questions
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Open questions and complex reflections
Number of subjects: 132
Study: 27578124

Group type: EXPERIMENTAL
Intervention: High-dose vitamin E supplementation (1200 IU/d for 12 weeks)
Number of subjects: 60
Study: 26598197

Group type: EXPERIMENTAL
Intervention: Subgingival air polishing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Manual scaling
Number of subjects: 31
Study: 21944571

Group type: EXPERIMENTAL
Intervention: Peer support worker (PSW) service
Number of subjects: 2724

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2724
Study: 20690154

Group type: EXPERIMENTAL
Intervention: Long hydrophilic-coated sheath
Number of subjects: 351

Group type: COMPARATOR
Intervention: Short sheath (control group)
Number of subjects: 351
Study: 18403134

Group type: EXPERIMENTAL
Intervention: Atomoxetine (25-100mg daily)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 15892078

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 12925458

Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 264

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 264
Study: 10802078

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate patches, 0.1 mg/h
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 88
Study: 8803306

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot (LA) 3.75 mg injected subcutaneously every 28 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Danazol 800 mg daily oral dose
Number of subjects: 45
Study: 1320563

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (two puffs qid 2 mg/puff)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 12
Study: 6829434

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31053215

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal (IR) + Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 108
Study: 29562846

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Empowerment program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine procedures
Number of subjects: 120
Study: 26974539

Group type: EXPERIMENTAL
Intervention: Test formulation of febuxostat 40-mg tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of febuxostat 40-mg tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test formulation of febuxostat 80-mg tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of febuxostat 80-mg tablet
Number of subjects: 24
Study: 25112082

Group type: EXPERIMENTAL
Intervention: Xunjingcuiqi needling technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 100
Study: 21546512

Group type: EXPERIMENTAL
Intervention: Two-quadrant technique (5 ml inferonasal and 5 ml superotemporal injection of 50:50 mixture of 2% lidocaine and 0.5% bupivacaine with 150 IU hyaluronidase)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Two-quadrant technique
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (standard 5 ml single inferonasal injection of 50:50 mixture of 2% lidocaine and 0.5% bupivacaine with 150 IU hyaluronidase)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 19876576

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the pelvic floor
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vaginal cone therapy
Number of subjects: 45
Study: 17245662

Group type: EXPERIMENTAL
Intervention: Self-help workbook based on behavioral principles, modified from the CRAFT model
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Self-help workbook plus telephone support
Number of subjects: 186

Group type: COMPARATOR
Intervention: Treatment resource information package (Control)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All interventions (Self-help workbook and Self-help workbook plus telephone support)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All groups (including Control)
Number of subjects: 186
Study: 15119980

Group type: EXPERIMENTAL
Intervention: Temazepam 7.5 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 131
Study: 11437205

Group type: EXPERIMENTAL
Intervention: Standing position with bi-optic scanner
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standing position with single window scanner
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitting position with bi-optic scanner
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sitting position with single window scanner
Number of subjects: 10
Study: 9543434

Group type: EXPERIMENTAL
Intervention: Monotherapy or combination therapy with ritonavir
Number of subjects: 131

Group type: COMPARATOR
Intervention: Monotherapy with ritonavir or combination therapy with ritonavir and zidovudine
Number of subjects: 131
Study: 8068834

Group type: EXPERIMENTAL
Intervention: Pairwise comparisons in multi-armed clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dunnett's or Tukey's procedure for multiple comparisons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bonferroni inequality approximation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequentially rejective procedure
Number of subjects: 0
Study: 2448358

Group type: EXPERIMENTAL
Intervention: terfenadine (120 mg, twice daily for 3 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 29606104

Group type: EXPERIMENTAL
Intervention: Ubiquinol and/or D-ribose administered for 12 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 27252841

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg 3 times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25527071

Group type: EXPERIMENTAL
Intervention: Tenofovir gel provision through family planning services
Number of subjects: 700

Group type: COMPARATOR
Intervention: Tenofovir gel provision through CAPRISA research clinics
Number of subjects: 700
Study: 22931627

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control (no epidural analgesia)
Number of subjects: 328
Study: 20837718

Group type: EXPERIMENTAL
Intervention: Mammographic screening from age 40, offered annually from age 40 or 41 to age 48.
Number of subjects: 53884

Group type: EXPERIMENTAL
Intervention: First routine screen
Number of subjects: 53884

Group type: EXPERIMENTAL
Intervention: Subsequent routine screens
Number of subjects: 53884

Group type: EXPERIMENTAL
Intervention: Cumulative false-positive rate over seven screens
Number of subjects: 53884

Group type: EXPERIMENTAL
Intervention: Previous false-positive recall
Number of subjects: 53884
Study: 17582225

Group type: EXPERIMENTAL
Intervention: 1.7 g DHA and 0.6 g EPA (omega3 group) daily for 6 months
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 204
Study: 17029137

Group type: EXPERIMENTAL
Intervention: Nonviable Lactobacillus acidophilus (LA)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 14582816

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 11314418

Group type: EXPERIMENTAL
Intervention: Gallium alloy (Galloy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High copper amalgam (DPI alloy)
Number of subjects: 50
Study: 8994319

Group type: EXPERIMENTAL
Intervention: 2 year old hepatitis A vaccine
Number of subjects: 215

Group type: COMPARATOR
Intervention: newly produced hepatitis A vaccine
Number of subjects: 215
Study: 1460210

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide at concentrations of 0.03% and 0.06%
Number of subjects: 0
Study: 6230296

Group type: EXPERIMENTAL
Intervention: Thymostimulin (1 mg/kg/day for seven days; 1 mg/kg/weekly thereafter)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects (not treated with Thymostimulin or untreated)
Number of subjects: 30
Study: 31257435

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention targeting health professionals' and patients' behaviour regarding antibiotic use.
Number of subjects: 309
Study: 29968556

Group type: EXPERIMENTAL
Intervention: Molecular diagnosis of samples
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Amplification of pfhrp2 exon-2
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Epitope mapping analysis
Number of subjects: 169
Study: 27113166

Group type: EXPERIMENTAL
Intervention: 10μg Hep-KSC
Number of subjects: 1731

Group type: COMPARATOR
Intervention: 10μg Engerix-B
Number of subjects: 1731

Group type: COMPARATOR
Intervention: 5μg Hep-KSC
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: 10μg Hep-KSC (PM Group)
Number of subjects: 1731

Group type: COMPARATOR
Intervention: 10μg Engerix-B (PM Group)
Number of subjects: 1731
Study: 23794225

Group type: EXPERIMENTAL
Intervention: Denosumab (administered once every 6 months for 36 months)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: COMPARATOR
Intervention: Denosumab vs Placebo
Number of subjects: 99